Replies to post #145582 on Biotech Values

[ghmm]

BMRN:

FYI (not a reason to be down, I don't think anyway :-)). This is what I think makes the buyout rumors hardest to value. GALNS can be solved with a CVR. While one could be creative for 701 (Pompe) there is really a wide range of outcomes from it not working to a biosimilar (JJ said they would outlicense) to something superior to myozyme/lumizyme which would make this potentially a bigger product than what GALNS could be. Its good it appears piper is pointing that out.

http://www.theflyonthewall.com/permalinks/entry.php/BMRNid1666823/BMRN-BioMarin-price-target-raised-to--from--at-Piper-Jaffray

BioMarin price target raised to $52 from $43 at Piper Jaffray
Piper Jaffray raised its price target for BioMarin citing the addition of BMN-701 to its model and expectations for a data-rich second half of 2012 for the company. Piper says positive Phase II data for BMN-701 for Pompe’s disease could send shares meaningfully higher and potentially lead to an acquisition of the company. The firm keeps an Overweight rating on BioMarin. :theflyonthewall.com